Title: Mortality rates and risk factors in 1,412 Japanese patients with decompensated hepatitis
C virus-related cirrhosis: A retrospective long-term cohort study
Version: 1 Date: 25 Dec 2020
Reviewer's report:
The authors performed a large study though the median follow up is rather limited (2 years).
However, the main issues with the study are (1) the lack of novelty since the natural history of
untreated HCC or decompensated liver disease in HCV patients have been well described and
(2) lack of clinical relevancy because the current practice is to treat these patients.  Data have
been overwhelming in regards to the high effectiveness and safety of DAA treatment for HCV
patients with decompensated liver disease including HCC. Thus, outcome data for untreated
patients are no longer clinically relevant.
Title: Mortality rates and risk factors in 1,412 Japanese patients with decompensated hepatitis
C virus-related cirrhosis: A retrospective long-term cohort study
Version: 1 Date: 25 Dec 2020
Reviewer's report:
The authors performed a large study though the median follow up is rather limited (2 years).
However, the main issues with the study are (1) the lack of novelty since the natural history of
untreated HCC or decompensated liver disease in HCV patients have been well described and
(2) lack of clinical relevancy because the current practice is to treat these patients.  Data have
been overwhelming in regards to the high effectiveness and safety of DAA treatment for HCV
patients with decompensated liver disease including HCC. Thus, outcome data for untreated
patients are no longer clinically relevant.
Please review this paper.
user
Title: Mortality rates and risk factors in 1,412 Japanese patients with decompensated hepatitis
C virus-related cirrhosis: A retrospective long-term cohort study
Version: 1 Date: 25 Dec 2020
Reviewer's report:
The authors performed a large study though the median follow up is rather limited (2 years).
However, the main issues with the study are (1) the lack of novelty since the natural history of
untreated HCC or decompensated liver disease in HCV patients have been well described and
(2) lack of clinical relevancy because the current practice is to treat these patients.  Data have
been overwhelming in regards to the high effectiveness and safety of DAA treatment for HCV
patients with decompensated liver disease including HCC. Thus, outcome data for untreated
patients are no longer clinically relevant.
assistant